phosphorylase (SEQ ID NO:1), wherein said antisense compound specifically hybridizes with and inhibits the expression of human liver glycogen phosphorylase.

REMARKS

This preliminary amendment is being made in response to a telephone interview with Examiner Schultz on August 28, 2002. Claim 3 has been canceled. Claim 1 has been amended to incorporate the SEQ ID NO. of the target sequence. This amendment to the claim is based on teachings throughout the specification as filed. No new matter has been added by this amendment.

Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

Respectfully submitted,

Jane Massey Licata
Registration No. 32,257

Date: **September 4, 2002**
Licata & Tyrrell P.C.
66 Main Street
Marlton, N.J. 08053
856-810-1515

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claim 3 has been canceled.

Claim 1 has been amended as follows:

1. (Amended) A compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human liver glycogen phosphorylase (SEQ ID NO:1), wherein said antisense compound specifically hybridizes with and inhibits the expression of human liver glycogen phosphorylase.